跳至主要内容
临床试验/EUCTR2011-004935-30-IT
EUCTR2011-004935-30-IT进行中(未招募)不适用

Study before-after”: Adherence Evaluation to antiretroviral therapy administered in two different ways: - EPIVIR (3TC) + VIREAD (TDF) versus TRUVADA (FTC + TDF) - EPIVIR (3TC) + ZIAGEN (ABC) versus KIVEXA (3TC + ABC) - EPIVIR (3TC) + RETROVIR (AZT) versus COMBIVIR (3TC + AZT) - EPIVIR (3TC) + VIREAD (TDF) + EFAVIRENZ (EFV) versus ATRIPLA (3TC + TDF + EFV)

.L.S.S. 9 DI TREVISO0 个研究点开始时间: 2012年3月8日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - age: at least 18 years old or older - patient treated with Truvada or Kivexa or Combivir and 3th drugs or Atripla for at least 6 months - Viral load < 20 cp/ml for at least 6 months - Patient able and willing to provide signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 400
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • patients who are at risk of non adherence (alcoholic abuse, intravenous drug users, dementia, language difficulties, homeless).

研究者

发起方
.L.S.S. 9 DI TREVISO

相似试验